Accountable.US Statement on House Republicans Burying Trump AG Pick Matt Gaetz’ Ethics Report
President-elect Trump’s Nomination of Dr. Oz Means Health Care At Risk for Seniors and Vulnerable Americans
At Least 5 People Associated with Project 2025 Tapped to Serve in the Trump Administration
Senate Hearing Highlights Need to End Visa-Mastercard Duopoly to Bring Competition, Lower Fees for Consumers and Small Business Owners
Trump and Republicans in Congress Double Down on Failed Economic System that Works for the Wealthy and Stiffs the Working Class
Site Menu

WASHINGTON, DC — Pharmaceutical giant Eli Lilly reported $2.19 billion in Q4 2023 net income today—a staggering amount made possible by aggressive price hikes against American seniors and patients. Eli Lilly raised overall prices in the United States by 27% in Q4 2023. 

“

Eli Lilly’s earnings today call into question big pharma’s claims the sky would fall if they lowered costs for patients in need. Their refusal to do so without regulatory intervention is a symptom of greed. While PhRMA—who represents Eli Lilly and their industry peers—sues to keep a rigged system in place, the Biden administration is taking significant strides to crack down on corporate price gouging and lower costs for millions of Americans.”

Accountable.US’ Tony Carrk

PhRMA, the largest pharmaceutical trade group, sued to block implementation of the Inflation Reduction Act’s Medicare negotiation program last year. Despite industry objections, the program is expected to save nearly 19 million seniors and other Medicare Part D enrollees $400 a year by 2025. 

back to top